-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the International Diabetes Federation (IDF), the number of adults aged 20 to 79 years old with diabetes worldwide reached 537 million
in 2021.
The prevalence of diabetes is high and the number of patients is large, so the market for hypoglycemic drugs is very large
.
in 2021.
The prevalence of diabetes is high and the number of patients is large, so the market for hypoglycemic drugs is very large
.
Since the use of animal insulin in 1922 to treat diabetes, in the past hundred years, about nine major types of diabetes treatment drugs have been developed worldwide, namely sulfonylureas, biguanides, α-glycosidase inhibitors, insulin, thiazolidinediones (TZDs), glinides, GLP-1RA, DPP-IV inhibitors, and SGLT-2 inhibitors
.
Among them, the performance of GLP-1RA drugs to reduce the level of glycosylated hemoglobin is extremely eye-catching, and the emergence of such drugs is expected to revolutionize the entire hypoglycemic drug market
.
From the current clinical application trend, GLP-1RA drugs have become hypoglycemic drugs
with great market potential in the industry.
.
Among them, the performance of GLP-1RA drugs to reduce the level of glycosylated hemoglobin is extremely eye-catching, and the emergence of such drugs is expected to revolutionize the entire hypoglycemic drug market
.
From the current clinical application trend, GLP-1RA drugs have become hypoglycemic drugs
with great market potential in the industry.
GLP-1RA has obvious advantages
GLP-1 (glucagon-like peptide-1) is a hormone secreted by the intestines during eating, which enhances insulin secretion in a glucose concentration-dependent manner, inhibits glucagon secretion, and can delay gastric emptying, reducing the amount of
food eaten through central appetite suppression.
GLP-1RA is a glucagon-like peptide-1 receptor agonist, which exerts the effect of lowering blood sugar by exciting GLP-1 receptors, which not only has a significant hypoglycemic effect, but also has the advantage of low incidence of
hypoglycemia.
In addition, because the tissues expressed by GLP-1 receptors are not limited to the gastrointestinal tract and pancreas, GLP-1RA can reduce the risk
of cardiovascular disease in addition to reducing sugar and weight.
Compared with insulin and most oral hypoglycemic drugs, GLP-1RA drugs have obvious
advantages.
food eaten through central appetite suppression.
GLP-1RA is a glucagon-like peptide-1 receptor agonist, which exerts the effect of lowering blood sugar by exciting GLP-1 receptors, which not only has a significant hypoglycemic effect, but also has the advantage of low incidence of
hypoglycemia.
In addition, because the tissues expressed by GLP-1 receptors are not limited to the gastrointestinal tract and pancreas, GLP-1RA can reduce the risk
of cardiovascular disease in addition to reducing sugar and weight.
Compared with insulin and most oral hypoglycemic drugs, GLP-1RA drugs have obvious
advantages.
The 2020 edition of the 2020 version of the Guidelines for the Prevention and Treatment of Type 2 Diabetes issued by the American Diabetes Association (ADA) recommends that patients with atherosclerotic cardiovascular disease (ASCVD) or diabetes with a higher risk of cardiovascular disease should be given priority to use GLP-1RA drugs, and GLP-1RA drugs
should be preferred when patients have needs to lower blood sugar and reduce obesity.
In 2019, the European Heart Association and the European Association for the Study of Diabetes recommended GLP-1 as the first-line treatment of choice for patients with combined ASCVD or high-risk/very high-risk cardiovascular risk
.
should be preferred when patients have needs to lower blood sugar and reduce obesity.
In 2019, the European Heart Association and the European Association for the Study of Diabetes recommended GLP-1 as the first-line treatment of choice for patients with combined ASCVD or high-risk/very high-risk cardiovascular risk
.
GLP-1RA is constantly being iteratively upgraded
In 2005, the world's first GLP-1RA drug Exendin-4 (exenatide) was approved by the U.
S.
Food and Drug Administration (FDA) for the adjuvant treatment of type 2 diabetes mellitus, with two injections
per day.
Since then, GLP-1RA drugs have embarked on the road of iterative upgrading
.
S.
Food and Drug Administration (FDA) for the adjuvant treatment of type 2 diabetes mellitus, with two injections
per day.
Since then, GLP-1RA drugs have embarked on the road of iterative upgrading
.
In 2009, Novo Nordisk's diabetes treatment liraglutide (liraglutide) was approved for marketing by the European Medicines Agency (EMA) and approved
by the FDA in 2010.
In addition to hypoglycemic effects, liraglutide has been shown to be both cardiovascular and beneficial
.
It is also the world's first GLP-1RA drug
to be injected once a day.
However, it was not until it entered the medical insurance directory in 2018 that the sales of liraglutide in China ushered in explosive growth
.
by the FDA in 2010.
In addition to hypoglycemic effects, liraglutide has been shown to be both cardiovascular and beneficial
.
It is also the world's first GLP-1RA drug
to be injected once a day.
However, it was not until it entered the medical insurance directory in 2018 that the sales of liraglutide in China ushered in explosive growth
.
To solve the problem of liraglutide injecting once a day, Eli Lilly has introduced Dulaglutide, which is administered once a week
.
The drug was approved by the FDA in 2014 for the treatment of type 2 diabetes
.
Since 2019, sales of doura glycopeptides have soared
.
.
The drug was approved by the FDA in 2014 for the treatment of type 2 diabetes
.
Since 2019, sales of doura glycopeptides have soared
.
In 2017, Novo Nordisk launched Semaglutide
.
As a blockbuster GLP-1RA drug, smeglutide extends the half-life to 7 days with a breakthrough technology that can be administered once
a week.
The drug has a good hypoglycemic effect in diabetic people, and a good weight loss effect in obese people, while also benefiting cardiovascular and kidney benefits
.
Smeglutide was once thought to be the ultimate product
in the field of GLP-1RA tracks and even type 2 diabetes treatment.
.
As a blockbuster GLP-1RA drug, smeglutide extends the half-life to 7 days with a breakthrough technology that can be administered once
a week.
The drug has a good hypoglycemic effect in diabetic people, and a good weight loss effect in obese people, while also benefiting cardiovascular and kidney benefits
.
Smeglutide was once thought to be the ultimate product
in the field of GLP-1RA tracks and even type 2 diabetes treatment.
In 2022, Eli Lilly launched the dual-target drug Tirzepatide (telsipatidide
).
The drug is a novel GLP-1RA/GIPR dual agonist administered subcutaneously once a week that activates both GLP-1 and GIP receptors
.
Among them, GIP (glucose-dependent insulin secretion polypeptide) is a hormone
that may complement the action of GLP-1 receptor agonists.
Preclinical studies have shown that GIP can reduce weight by reducing food intake and increasing energy consumption, and binding to GLP-1 receptor agonists may have a greater impact on
patients' blood glucose and weight.
).
The drug is a novel GLP-1RA/GIPR dual agonist administered subcutaneously once a week that activates both GLP-1 and GIP receptors
.
Among them, GIP (glucose-dependent insulin secretion polypeptide) is a hormone
that may complement the action of GLP-1 receptor agonists.
Preclinical studies have shown that GIP can reduce weight by reducing food intake and increasing energy consumption, and binding to GLP-1 receptor agonists may have a greater impact on
patients' blood glucose and weight.
Tescipapate was known for its head-to-head study of SURPASS-2 with smeglutide
.
The study compared the hypoglycemic effects
of telcipapate 5 mg, 10 mg and 15 mg with smeglerutide 1 mg.
The results showed that compared with baseline A1C (glycosylated hemoglobin) levels (8.
3%), tisipapeptide reduced subjects' A1C by an average of 2.
0%, 2.
2% and 2.
3%, while smegluotide decreased by an average of 1.
9%; In terms of weight loss, tisipatide reduced subjects by an average of 17 pounds, 21 pounds, and 25 pounds compared to a baseline weight of 207 pounds, compared to a baseline weight of 13 pounds
.
The success of challenging smeglutide means that a new round of market change is coming, and tesithipapeptide, as the leader of dual-target agonist hypoglycemic drugs, may become the core competitive product in
the field of follow-up hypoglycemic reduction.
.
The study compared the hypoglycemic effects
of telcipapate 5 mg, 10 mg and 15 mg with smeglerutide 1 mg.
The results showed that compared with baseline A1C (glycosylated hemoglobin) levels (8.
3%), tisipapeptide reduced subjects' A1C by an average of 2.
0%, 2.
2% and 2.
3%, while smegluotide decreased by an average of 1.
9%; In terms of weight loss, tisipatide reduced subjects by an average of 17 pounds, 21 pounds, and 25 pounds compared to a baseline weight of 207 pounds, compared to a baseline weight of 13 pounds
.
The success of challenging smeglutide means that a new round of market change is coming, and tesithipapeptide, as the leader of dual-target agonist hypoglycemic drugs, may become the core competitive product in
the field of follow-up hypoglycemic reduction.
The domestic GLP-1RA market is to be tapped
According to public data from IDF, the number of adult diabetic patients aged 20 to 79 in China will exceed 140 million
in 2021.
At present, GLP-1RA has undergone several update iterations, and more than 10 related products
have been approved and listed worldwide.
However, most of the market share of diabetes drugs in China is still occupied by traditional drugs, and GLP-1RA drugs occupy a small market share
.
Diabetes is prone to cause large vascular lesions, microangiopathy and other complications, which seriously affect the quality of life of patients and increase the burden
of disease.
Therefore, GLP-1RA drugs with significant hypoglycemic effects and multiple benefits are becoming more and more popular, and the domestic market needs to be further explored
.
in 2021.
At present, GLP-1RA has undergone several update iterations, and more than 10 related products
have been approved and listed worldwide.
However, most of the market share of diabetes drugs in China is still occupied by traditional drugs, and GLP-1RA drugs occupy a small market share
.
Diabetes is prone to cause large vascular lesions, microangiopathy and other complications, which seriously affect the quality of life of patients and increase the burden
of disease.
Therefore, GLP-1RA drugs with significant hypoglycemic effects and multiple benefits are becoming more and more popular, and the domestic market needs to be further explored
.
In recent years, clinical guidelines related to diabetes treatment at home and abroad have unanimously defined the important therapeutic status
of GLP-1RA drugs for patients with type 2 diabetes with cardiovascular disease or cardiovascular risk.
With the gradual strengthening of clinical evidence, GLP-1RA drugs are expected to benefit more type 2 diabetic patients in China, and the market size will be further expanded
.
(Source: Ameda Pharmaceutical Consulting)
of GLP-1RA drugs for patients with type 2 diabetes with cardiovascular disease or cardiovascular risk.
With the gradual strengthening of clinical evidence, GLP-1RA drugs are expected to benefit more type 2 diabetic patients in China, and the market size will be further expanded
.
(Source: Ameda Pharmaceutical Consulting)
According to the International Diabetes Federation (IDF), the number of adults aged 20 to 79 years old with diabetes worldwide reached 537 million
in 2021.
The prevalence of diabetes is high and the number of patients is large, so the market for hypoglycemic drugs is very large
.
in 2021.
The prevalence of diabetes is high and the number of patients is large, so the market for hypoglycemic drugs is very large
.
Since the use of animal insulin in 1922 to treat diabetes, in the past hundred years, about nine major types of diabetes treatment drugs have been developed worldwide, namely sulfonylureas, biguanides, α-glycosidase inhibitors, insulin, thiazolidinediones (TZDs), glinides, GLP-1RA, DPP-IV inhibitors, and SGLT-2 inhibitors
.
Among them, the performance of GLP-1RA drugs to reduce the level of glycosylated hemoglobin is extremely eye-catching, and the emergence of such drugs is expected to revolutionize the entire hypoglycemic drug market
.
From the current clinical application trend, GLP-1RA drugs have become hypoglycemic drugs
with great market potential in the industry.
.
Among them, the performance of GLP-1RA drugs to reduce the level of glycosylated hemoglobin is extremely eye-catching, and the emergence of such drugs is expected to revolutionize the entire hypoglycemic drug market
.
From the current clinical application trend, GLP-1RA drugs have become hypoglycemic drugs
with great market potential in the industry.
GLP-1RA has obvious advantages
GLP-1RA has obvious advantages GLP-1 (glucagon-like peptide-1) is a hormone secreted by the intestines during eating, which enhances insulin secretion in a glucose concentration-dependent manner, inhibits glucagon secretion, and can delay gastric emptying, reducing the amount of
food eaten through central appetite suppression.
GLP-1RA is a glucagon-like peptide-1 receptor agonist, which exerts the effect of lowering blood sugar by exciting GLP-1 receptors, which not only has a significant hypoglycemic effect, but also has the advantage of low incidence of
hypoglycemia.
In addition, because the tissues expressed by GLP-1 receptors are not limited to the gastrointestinal tract and pancreas, GLP-1RA can reduce the risk
of cardiovascular disease in addition to reducing sugar and weight.
Compared with insulin and most oral hypoglycemic drugs, GLP-1RA drugs have obvious
advantages.
Diseases and diseasesfood eaten through central appetite suppression.
GLP-1RA is a glucagon-like peptide-1 receptor agonist, which exerts the effect of lowering blood sugar by exciting GLP-1 receptors, which not only has a significant hypoglycemic effect, but also has the advantage of low incidence of
hypoglycemia.
In addition, because the tissues expressed by GLP-1 receptors are not limited to the gastrointestinal tract and pancreas, GLP-1RA can reduce the risk
of cardiovascular disease in addition to reducing sugar and weight.
Compared with insulin and most oral hypoglycemic drugs, GLP-1RA drugs have obvious
advantages.
The 2020 edition of the 2020 version of the Guidelines for the Prevention and Treatment of Type 2 Diabetes issued by the American Diabetes Association (ADA) recommends that patients with atherosclerotic cardiovascular disease (ASCVD) or diabetes with a higher risk of cardiovascular disease should be given priority to use GLP-1RA drugs, and GLP-1RA drugs
should be preferred when patients have needs to lower blood sugar and reduce obesity.
In 2019, the European Heart Association and the European Association for the Study of Diabetes recommended GLP-1 as the first-line treatment of choice for patients with combined ASCVD or high-risk/very high-risk cardiovascular risk
.
Heart heartshould be preferred when patients have needs to lower blood sugar and reduce obesity.
In 2019, the European Heart Association and the European Association for the Study of Diabetes recommended GLP-1 as the first-line treatment of choice for patients with combined ASCVD or high-risk/very high-risk cardiovascular risk
.
GLP-1RA is constantly being iteratively upgraded
GLP-1RA is constantly being iteratively upgraded In 2005, the world's first GLP-1RA drug Exendin-4 (exenatide) was approved by the U.
S.
Food and Drug Administration (FDA) for the adjuvant treatment of type 2 diabetes mellitus, with two injections
per day.
Since then, GLP-1RA drugs have embarked on the road of iterative upgrading
.
PharmaceuticalsS.
Food and Drug Administration (FDA) for the adjuvant treatment of type 2 diabetes mellitus, with two injections
per day.
Since then, GLP-1RA drugs have embarked on the road of iterative upgrading
.
In 2009, Novo Nordisk's diabetes treatment liraglutide (liraglutide) was approved for marketing by the European Medicines Agency (EMA) and approved
by the FDA in 2010.
In addition to hypoglycemic effects, liraglutide has been shown to be both cardiovascular and beneficial
.
It is also the world's first GLP-1RA drug
to be injected once a day.
However, it was not until it entered the medical insurance directory in 2018 that the sales of liraglutide in China ushered in explosive growth
.
by the FDA in 2010.
In addition to hypoglycemic effects, liraglutide has been shown to be both cardiovascular and beneficial
.
It is also the world's first GLP-1RA drug
to be injected once a day.
However, it was not until it entered the medical insurance directory in 2018 that the sales of liraglutide in China ushered in explosive growth
.
To solve the problem of liraglutide injecting once a day, Eli Lilly has introduced Dulaglutide, which is administered once a week
.
The drug was approved by the FDA in 2014 for the treatment of type 2 diabetes
.
Since 2019, sales of doura glycopeptides have soared
.
.
The drug was approved by the FDA in 2014 for the treatment of type 2 diabetes
.
Since 2019, sales of doura glycopeptides have soared
.
In 2017, Novo Nordisk launched Semaglutide
.
As a blockbuster GLP-1RA drug, smeglutide extends the half-life to 7 days with a breakthrough technology that can be administered once
a week.
The drug has a good hypoglycemic effect in diabetic people, and a good weight loss effect in obese people, while also benefiting cardiovascular and kidney benefits
.
Smeglutide was once thought to be the ultimate product
in the field of GLP-1RA tracks and even type 2 diabetes treatment.
.
As a blockbuster GLP-1RA drug, smeglutide extends the half-life to 7 days with a breakthrough technology that can be administered once
a week.
The drug has a good hypoglycemic effect in diabetic people, and a good weight loss effect in obese people, while also benefiting cardiovascular and kidney benefits
.
Smeglutide was once thought to be the ultimate product
in the field of GLP-1RA tracks and even type 2 diabetes treatment.
In 2022, Eli Lilly launched the dual-target drug Tirzepatide (telsipatidide
).
The drug is a novel GLP-1RA/GIPR dual agonist administered subcutaneously once a week that activates both GLP-1 and GIP receptors
.
Among them, GIP (glucose-dependent insulin secretion polypeptide) is a hormone
that may complement the action of GLP-1 receptor agonists.
Preclinical studies have shown that GIP can reduce weight by reducing food intake and increasing energy consumption, and binding to GLP-1 receptor agonists may have a greater impact on
patients' blood glucose and weight.
).
The drug is a novel GLP-1RA/GIPR dual agonist administered subcutaneously once a week that activates both GLP-1 and GIP receptors
.
Among them, GIP (glucose-dependent insulin secretion polypeptide) is a hormone
that may complement the action of GLP-1 receptor agonists.
Preclinical studies have shown that GIP can reduce weight by reducing food intake and increasing energy consumption, and binding to GLP-1 receptor agonists may have a greater impact on
patients' blood glucose and weight.
Tescipapate was known for its head-to-head study of SURPASS-2 with smeglutide
.
The study compared the hypoglycemic effects
of telcipapate 5 mg, 10 mg and 15 mg with smeglerutide 1 mg.
The results showed that compared with baseline A1C (glycosylated hemoglobin) levels (8.
3%), tisipapeptide reduced subjects' A1C by an average of 2.
0%, 2.
2% and 2.
3%, while smegluotide decreased by an average of 1.
9%; In terms of weight loss, tisipatide reduced subjects by an average of 17 pounds, 21 pounds, and 25 pounds compared to a baseline weight of 207 pounds, compared to a baseline weight of 13 pounds
.
The success of challenging smeglutide means that a new round of market change is coming, and tesithipapeptide, as the leader of dual-target agonist hypoglycemic drugs, may become the core competitive product in
the field of follow-up hypoglycemic reduction.
.
The study compared the hypoglycemic effects
of telcipapate 5 mg, 10 mg and 15 mg with smeglerutide 1 mg.
The results showed that compared with baseline A1C (glycosylated hemoglobin) levels (8.
3%), tisipapeptide reduced subjects' A1C by an average of 2.
0%, 2.
2% and 2.
3%, while smegluotide decreased by an average of 1.
9%; In terms of weight loss, tisipatide reduced subjects by an average of 17 pounds, 21 pounds, and 25 pounds compared to a baseline weight of 207 pounds, compared to a baseline weight of 13 pounds
.
The success of challenging smeglutide means that a new round of market change is coming, and tesithipapeptide, as the leader of dual-target agonist hypoglycemic drugs, may become the core competitive product in
the field of follow-up hypoglycemic reduction.
The domestic GLP-1RA market is to be tapped
The domestic GLP-1RA market is to be tapped According to public data from IDF, the number of adult diabetic patients aged 20 to 79 in China will exceed 140 million
in 2021.
At present, GLP-1RA has undergone several update iterations, and more than 10 related products
have been approved and listed worldwide.
However, most of the market share of diabetes drugs in China is still occupied by traditional drugs, and GLP-1RA drugs occupy a small market share
.
Diabetes is prone to cause large vascular lesions, microangiopathy and other complications, which seriously affect the quality of life of patients and increase the burden
of disease.
Therefore, GLP-1RA drugs with significant hypoglycemic effects and multiple benefits are becoming more and more popular, and the domestic market needs to be further explored
.
in 2021.
At present, GLP-1RA has undergone several update iterations, and more than 10 related products
have been approved and listed worldwide.
However, most of the market share of diabetes drugs in China is still occupied by traditional drugs, and GLP-1RA drugs occupy a small market share
.
Diabetes is prone to cause large vascular lesions, microangiopathy and other complications, which seriously affect the quality of life of patients and increase the burden
of disease.
Therefore, GLP-1RA drugs with significant hypoglycemic effects and multiple benefits are becoming more and more popular, and the domestic market needs to be further explored
.
In recent years, clinical guidelines related to diabetes treatment at home and abroad have unanimously defined the important therapeutic status
of GLP-1RA drugs for patients with type 2 diabetes with cardiovascular disease or cardiovascular risk.
With the gradual strengthening of clinical evidence, GLP-1RA drugs are expected to benefit more type 2 diabetic patients in China, and the market size will be further expanded
.
(Source: Ameda Pharmaceutical Consulting)
Medicine of GLP-1RA drugs for patients with type 2 diabetes with cardiovascular disease or cardiovascular risk.
With the gradual strengthening of clinical evidence, GLP-1RA drugs are expected to benefit more type 2 diabetic patients in China, and the market size will be further expanded
.
(Source: Ameda Pharmaceutical Consulting)
